Contribution of nosocomial transmission to *Klebsiella pneumoniae* neonatal sepsis in Africa and South Asia: analysis of infection clusters inferred from pathogen genomics and temporal data

Short title: Transmission of *Klebsiella pneumoniae* causing invasive disease in neonatal
units

Erkison Ewomazino Odih[1], Jabir A Abdulahi[2], Anne V Amulele[3], Matthew Bates[4], Eva
Heinz[5,6], Weiming Hu[7], Kajal Jain[8], Rindidzani Magobo[9,10], Courtney P Olwagen[11], John M
Tembo[12], Tolbert Sonda[13], Jonathan Strysko[14,15], Caroline C Tigoi[3], Kyle Bittinger[7,16,17],
Jennifer Cornick[18,19], Ebenezer Foster-Nyarko[1], Wilson Gumbi[3], Steven M Jones[7], Chileshe
L Musyani[20,21], Carolyn M McGann[22,16], Ahmed M Moustafa[7,16,17], Patrick Musicha[19,23], James
CL Mwansa[24], Moreka L Ndumba[3], Thomas D Stanton[25,26], Donwilliams O Omuoyo[3], Oliver
Pearse[19,23], Laura T Phillips[1], Paul J Planet[16,17,27], Charlene MC Rodrigues[1,28,29], Fatou
Secka[1], Kirsty Sands[30,31], Erin Theiller[17], Allan M Zuza[19,32], Sulagna Basu[33], Grace J Chan[34],
Kenneth C Iregbu[35,36], Jean-Baptiste Mazarati[37,38], Semaria Solomon Alemayehu[39], Timothy
R Walsh[30,40], Rabaab Zahra[41,42], Angela Dramowski[43], Sombo Fwoloshi[44], Appiah-Korang
Labi[45], Lola Madrid[2,46], Noah Obeng-Nkrumah[47], David Ojok[48], Boaz D Wadugu[49], Andrew C
Whitelaw[50,51], Anudita Bhargava[52], Atul Jindal[53], Ramesh K Agarwal[8], Alexander M Aiken[2],
James A Berkley[54,55], Susan E Coffin[16,56], Nicholas A Feasey[19,27], Nelesh P Govender[9, 32],
Davidson H Hamer[57,58], Shabir A Madhi[11,59], M Jeeva Sankar[8], Kelly L Wyres[1,25,26], Kathryn E
Holt[1,25,*]
23
1 Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK
2 Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and
Tropical Medicine, London, UK
3 Bioscience Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
4 School of Natural Sciences, University of Lincoln, Lincoln, UK
5 Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK
6 Parasites and Microbes Program, Wellcome Sanger Institute, Hinxton, UK
7 Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, USA
8 Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
9 National Institute for Communicable Diseases, a Division of the National Health Laboratory Service,
Johannesburg, South Africa
10 Division of Public Health, Societies and Belonging, Human Sciences Research Council, Pretoria, South Africa
11 South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty
of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
12 Infectious Diseases, HerpeZ, Lusaka, Zambia
13 Bioinformatics Unit, Kilimanjaro Clinical Research Institute, Moshi, Tanzania
14 Botswana-University of Pennsylvania Partnership, University of Pennsylvania, Gaborone, Botswana
15 Division of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
16 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
17 Center for Microbial Medicine, Children's Hospital of Philadelphia, Philadelphia, USA
18 Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK
19 Malawi Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi
20 Antimicrobial Resistance Unit, Zambia National Public Health Institute, Lusaka, Zambia
21 Levy Mwanawasa Medical University, Lusaka, Zambia
22 Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, USA
23 Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
24 Directorate of Research and Post Graduate Studies, Lusaka Apex Medical University, Lusaka, Zambia

25 Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne,
Australia
26 Centre to Impact AMR, Monash University, Clayton, Victoria, Australia
27 The School of Medicine, University of St Andrews, St Andrews, UK
28 Department of Paediatrics, Imperial College Healthcare NHS Trust, London, UK
29 Pathogen Genomics Programme, UK Health Security Agency, London, UK
30 Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK
31 Department of Medical Microbiology, Division of Infection and Immunity, Cardiff University, Cardiff, UK
32 Wits Mycology Division, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South
Africa
33 Division of Bacteriology, ICMR-National Institute for Research in Bacterial Infections (formerly ICMR-NICED),
Kolkata, India
34 Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, USA
35 Medical Microbiology, University of Abuja, Abuja, Nigeria
36 National Hospital Abuja, Abuja, Nigeria
37 Health Sciences, INES-RUHENGERI, Musanze, Rwanda
38 INES Centre for Genomic Biology, Musanze, Rwanda
39 Department of Microbiology, Immunology and Parasitology, St. Paul's Hospital Millennium Medical College,
Addis Ababa, Ethiopia
40 International Centre for Antimicrobial Resistance Solutions, Copenhagen, Denmark
41 Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan
42 Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, St James's Hospital, Dublin 8,
Ireland
43 Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa
44 University Teaching Hospital, University of Zambia, School of Medicine, Lusaka, Zambia
45 Department of Medical Microbiology, University of Ghana Medical School, Accra, Ghana
46 College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
47 Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, College of
Health Sciences, University of Ghana, Accra, Ghana
48 Central Laboratory, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
49 Biotechnology Laboratory, Kilimanjaro Clinical Research Institute, Moshi, Tanzania
50 Medical Microbiology and Immunology, Faculty of Medicine and Health Sciences, Stellenbosch University,
Cape Town, South Africa
51 National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa
52 Microbiology, All India Institute of Medical Sciences, Raipur, India
53 Pediatrics, All India Institute of Medical Sciences, Raipur, India
54 Nuffield Department of Medicine, University of Oxford, Oxford, UK
55 Clinical Research Department, KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya
56 Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, USA
57 Department of Global Health, Boston University School of Public Health, Boston, MA, USA
58 Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, MA,
USA
59 Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the
Witwatersrand, Johannesburg, South Africa
95
96
97   * Corresponding author
98   Email: kat.holt@lshtm.ac.uk

Abstract

Background

Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial resistant (AMR) infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of *K. pneumoniae* neonatal sepsis attributable to nosocomial transmission in African and South Asian countries.

Methods and Findings

We estimated the proportion of invasive *K. pneumoniae* disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences aggregated from 10 contributing studies. Analysing 1,523 *K. pneumoniae* isolates from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs, including several globally recognised multidrug-resistant lineages, were associated with transmission clusters at multiple units and these were collectively responsible for two-thirds of all infections. Carriage of

carbapenemase genes (adjusted odds ratio, aOR = 2.08 [95% confidence interval, CI: 1.04–

4.14], p=0.02) and ESBL genes (aOR = 2.48 [95% CI: 1.26–4.90] p=0.006) were significantly

positively associated with transmission.

Conclusions

Nosocomial transmission contributes to a substantial proportion of *K. pneumoniae* sepsis in

neonatal care units in Africa and South Asia. Reducing transmission within these settings

through improved infection prevention and control and other measures could substantially

reduce the neonatal sepsis burden. A high burden of transmission clusters is associated with

the same drug-resistant lineages that are recognised as high-risk clones associated with

hospital outbreaks in high-income countries, indicating global connectivity of the AMR

pathogen population.

Keywords: *Klebsiella pneumoniae*; neonatal sepsis; transmission; outbreak; Africa; South

Asia; pathogen sequencing; genomics

Author Summary

Why Was This Study Done?

- *Klebsiella pneumoniae* is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, and the infections are difficult to treat due to rising rates of antimicrobial resistance.

- Invasive bacterial diseases are typically transmitted to neonates from their mothers before, during or soon after birth (vertical transmission) or from the hospital environment and healthcare workers (horizontal transmission).

- The fraction of *K. pneumoniae* neonatal sepsis cases attributable to horizontal transmission is unknown, but this information is important to understand the role of infection prevention and control (IPC) measures in lowering disease burden.

What Did the Researchers Do and Find?

- We developed a simple method to detect transmission clusters from genetic and temporal distance data and found the method to be robust to the choice of genetic and temporal distance thresholds.

- We applied this method to detect transmission clusters among 1,523 *K. pneumoniae* neonatal sepsis cases from 10 studies and 27 hospitals across Africa and South Asia.

- We estimate over half of sepsis cases (68.0%) were part of a transmission cluster, and by excluding the hypothetical index case for each cluster we estimate at least 57.7% of infections were acquired via nosocomial transmission.

- Most of the isolates (90.9%) were extended-spectrum beta-lactamase (ESBL) producers (conferring resistance to third-generation cephalosporin antibiotics), and carriage of ESBL and carbapenemase genes (conferring resistance to carbapenem antibiotics) were positively associated with transmission.

- Fourteen genetic lineages were associated with clusters in multiple neonatal units, together accounting for two-thirds of all infections.

- Many of these same lineages are common causes of drug-resistant hospital outbreaks in high-income countries.

What Do These Findings Mean?

- A substantial proportion of *K. pneumoniae* neonatal sepsis cases are potentially preventable with improvements in IPC in neonatal units.

- Further work is needed to identify and better understand transmission routes and risk factors for transmission to support the implementation of effective and scalable IPC solutions.

- Our findings highlight the importance of genomic surveillance to support IPC interventions for *K. pneumoniae* and other pathogens, and reveal many of the same 'drug-resistant problem clones' are responsible for hospital outbreaks across high- and low-income countries.

- The high rates of ESBL gene carriage among isolates in this study indicates that empirical treatment based on the current WHO guidelines may result in high rates of treatment failure.

184   ● The limitations of this study include the lack of sufficient clinical data to allow high-
185   resolution investigation of transmission dynamics, as well as facility-level data to
186   investigate contributors to the observed differences in transmission burden across
187   sites.

Introduction

Sepsis is a leading cause of death among neonates, particularly in Africa and Asia, where the highest global incidence of neonatal mortality was recorded in 2022, with over 21 deaths per 1000 live births [1–3]. Bacterial infections are the most common cause of neonatal sepsis globally, with the predominant pathogens varying across geographical regions [4–10]. In Africa and Asia, *K. pneumoniae* is the primary cause of neonatal sepsis, and displays high rates of resistance to empirical antimicrobials recommended by WHO [5,11]. This makes the infections difficult to treat which contributes to higher neonatal mortality rates, mostly in low- and middle-income countries (LMICs) where the disease burden is highest and access to high-quality medical care and effective antibiotics is often limited [12,13].

Invasive bacterial disease in neonates is associated with two main transmission routes; vertical transmission from the mother, and horizontal transmission from other sources including the hospital environment and healthcare workers [8,14,15]. As such, efforts to reduce the burden of neonatal sepsis focus on intrapartum antimicrobial prophylaxis [16], improving infection prevention and control (IPC) practices, early case identification, and sepsis management [17].

K. pneumoniae is well-established as a leading cause of nosocomial infection outbreaks in hospitals globally [18], more likely to cause clusters than *Escherichia coli* or other Gram negatives [19]. *K. pneumoniae* outbreaks in neonatal care units are well documented in the literature, including the use of pathogen whole-genome sequencing (WGS) to resolve transmission patterns and identify infection sources [20–25]. Nosocomial transmission in LMICs have been linked to poor IPC practices often resulting from limited resources, including inadequate access to water, sanitation, and hygiene, ineffective ward cleaning and sharing of beds and equipment [26–28]. In a retrospective WGS study of *K. pneumoniae* bloodstream infections over 20 years in a single hospital in Malawi, the majority (77%) of cases due to key lineages investigated (ST14, ST15, ST35, ST39) were attributable to

nosocomial transmission, suggesting that more effective IPC practices supported by

investment in IPC resources could help limit the incidence of neonatal sepsis [22].

To our knowledge, no study has quantified the contribution of nosocomial transmission to the

burden of hospital-based *K. pneumoniae* neonatal sepsis across LMICs. This information is

crucial to understand and contextualise the role of effective IPC measures in lowering the

burden of neonatal sepsis in these settings, which is increasingly important as rising AMR

further reduces treatment options. To address this gap, this study aimed to estimate the

proportion of *K. pneumoniae* neonatal sepsis infections that are attributable to nosocomial

transmission in neonatal care settings in LMICs in Africa and Asia.

225 Methods

226 Ethical considerations

Each contributing study obtained local ethical approval, details of ethics committees and

approval numbers are listed in **S1 Table**. The Baby GERMS-SA [29] and Malawi-Liverpool-

Wellcome (MLW) Biobank [22] studies were granted consent waivers from local ethics

committees for the use of routine diagnostic specimens/isolates and routine clinical data for

research; all other studies obtained informed consent from the parents of participating

neonates. Approval for the cross-study analysis presented here was granted by the

Observational / Interventions Research Ethics Committee of the London School of Hygiene

and Tropical Medicine (ref #29931). Anonymised data from each primary study were shared

for analysis, including date of specimen collection and hospital site identifier (where the

study included more than one site), along with pathogen WGS data for the corresponding

bacterial isolate.

Bacterial isolates and sequence analysis

Whole-genome sequences of *K. pneumoniae* isolated from neonates in LMICs in Asia and Africa were sourced from prospective clinical studies of neonatal sepsis: Burden of Antibiotic Resistance in Neonates from Developing Societies (BARNARDS) [5], Sepsis Prevention in Neonates in Zambia (SPINZ) [30–32], Baby GERMS-SA [29,33], Mortality from Bacterial Infections Resistant to Antibiotics (MBIRA) [34], Indian District Hospitals (DH) [35], Group B Strep Correlates of Protection Study (GBS-COP) [36], Neonatal Infections & MicroBIome (NIMBI-plus) [37], NeoBAC [38]; and long-term prospective surveillance of bloodstream infection at Queen Elizabeth Central Hospital in Blantyre, Malawi (MLW Biobank) [22] and Kilifi County Teaching and Referral Hospital (KCTRH) carried out by the Kenya Medical Research Institute (KEMRI)/Wellcome Trust Research Programme (KWTRP) [38]. All included studies were undertaken as observational or surveillance studies aiming to capture all blood culture-positive sepsis cases during a defined period, not specifically instigated to investigate or respond to outbreaks. These studies and the corresponding whole-genome sequence data are a subset of those included in a meta-analysis of K and O antigen prevalence amongst *K. pneumoniae* causing neonatal sepsis in LMICs published in 2026 [39]. That study adjusted for within-unit clustering to minimise the impact of localised transmission events on the estimation of regional antigen prevalence, but did not investigate transmission as a phenomenon, which is the goal of the present study. Details of samples included from each study are given in **Table 1**, and characteristics of each study site are given in **Table 2** (this represents information provided by co-authors from each study team). We used the United Nations Statistics Division M49 standard to assign countries to geographical sub-regions (Asian countries) and intermediate regions (African countries) [40].

Table 1. Summary of isolates included in the study

Region	Country	Study [Ref]	Site no.	No. *Kpn* genomes	No. sepsis isolates	Year of study	Temporal span (weeks)
Eastern Africa	*All*	-	-	**1124**	-	-	-
	Ethiopia	BARNARDS [5]	Site 1	94	443	2017	39
		MBIRA [34]	Site 2	31	n/a	2021	30
	Kenya	KWTRP [38]	Site 3	167	689	2013 - 2023	537
		NeoBAC [38]	Site 4	46	77	2021 - 2022	40
		NeoBAC [38]	Site 5	20	83	2021 - 2022	60
	Malawi	MBIRA [34]	Site 6A	27	n/a	2020 - 2021	55
		MLW [22]	Site 6B	362	n/a	2013 - 2020	377
	Rwanda	BARNARDS [5]	Site 7	15	240	2016 - 2017	79
	Tanzania	MBIRA [34]	Site 8	58	n/a	2021	39
	Zambia	MBIRA [34]	Site 9	19	n/a	2021	36
		SPINZ [30–32]	Site 10	285	424	2015 - 2017	72
Western Africa	*All*	-	-	**75**	-	-	-
	Ghana	MBIRA [34]	Site 11	25	n/a	2020 - 2021	45
	Nigeria	BARNARDS [5]	Site 12	34	228	2016 - 2017	96
		BARNARDS [5]	Site 13	16	315	2017	41
Southern Africa	*All*	-	-	**243**	-	-	-
	Botswana	NIMBI-plus [37]	Site 14	29	96	2022 - 2023	74
	South Africa	BARNARDS [5]	Site 15A	12	94	2016 - 2017	77
		Baby GERMS-SA [29,33]	Site 16	34	190	2019 - 2020	51
		Baby GERMS-SA [29,33]	Site 17	27	93	2019 - 2020	45
		Baby GERMS-SA [29,33]	Site 18	23	143	2019 - 2020	47
		Baby GERMS-SA [29,33]	Site 19	22	116	2019 - 2020	47
		Baby GERMS-SA [29,33]	Site 20	21	237	2019 - 2020	49
		Baby GERMS-SA [29,33]	Site 21	13	128	2019 - 2020	34
		GBS-COP [36]	Site 22	49	70	2019 - 2020	69
		MBIRA [34]	Site 15B	13	172	2021	25
South Asia	*All*	-	-	**81**	-	-	-
	Bangladesh	BARNARDS [5]	Site 23	17	192	2016 - 2017	89
	India	DH [35]	Site 24	34	141	2019 - 2022	116
	Pakistan	BARNARDS [5]	Site 25	30	767	2016 - 2017	81
Total	-	-	-	**1523**	-	-	-

Sites 6A and 6B represent the same neonatal unit that was included in two separate study protocols spanning different time periods as shown; data from these studies were treated separately in the analysis, as sample collection and WGS protocols were conducted separately. Similarly, sites 15A and 15B represent the same neonatal unit that was included in two distinct studies. The "No. sepsis isolates" column shows the total number of culture-positive (regardless of pathogen) blood/cerebrospinal fluid samples from neonates in each site during the respective sampling periods. *Kpn* – *Klebsiella pneumoniae*, n/a – not available.

269 **Table 2. Characteristics of facilities included in the study**

Region	Country	Location	Facility size	No. neonatal beds	Piped water available	Onsite neonatal surgical facilities	Site
Eastern Africa	Ethiopia	Urban	Very Large	30	Sometimes	Yes	Site 1
		Urban	Medium	40	Sometimes	Yes	Site 2
	Kenya	Rural	Large	75	Always	Yes	Site 3
		Urban	Large	100	Always	No	Site 4
		Urban	Large	90	Always	No	Site 5
	Malawi	Urban	Very Large	70	Mostly	Yes	Site 6A/6B
	Rwanda	Rural	Medium	15	Always	Yes	Site 7
	Tanzania	Urban	Very Large	100	Always	Yes	Site 8
	Zambia	Urban	Large	57	Mostly	Yes	Site 9
		Urban	Very Large	60	Sometimes	Yes	Site 10
Western Africa	Ghana	Urban	Very Large	55	Always	Yes	Site 11
	Nigeria	Urban	Very Large	30	Mostly	Yes	Site 12
		Urban	Large	20	Always	Yes	Site 13
Southern Africa	Botswana	Urban	Large	36	Mostly	Yes	Site 14
	South Africa	Urban	Very Large	132	Always	Yes	Site 15A/15B
		Urban	Very Large	71	Always	Yes	Site 16
		Urban	Large	36	Always	Yes	Site 17
		Urban	Large	72	Always	Yes	Site 18
		Urban	Large	45	Always	Yes	Site 19
		Urban	Large	60	Always	Yes	Site 20
		Urban	Large	92	Always	Yes	Site 21
		Urban	Very Large	200	Always	Yes	Site 22
South Asia	Bangladesh	Urban	Very Large	80	Mostly	Yes	Site 23
	India	Urban	Small	12	Always	No	Site 24
	Pakistan	Urban	Large	30	Always	Yes	Site 25

270 Facility size (total number of beds) – Small: 50–150 beds, Medium: 151–300 beds, Large: 301–600 beds, Very
271 Large: >600 beds

For the prospective studies (BARNARDS, SPINZ, Baby GERMS-SA, MBIRA, DH, GBS-COP, NIMBI-plus, NeoBAC), blood culture was performed for all neonates with clinically suspected sepsis, and all blood culture isolates identified as *Klebsiella* that could be later revived for DNA extraction were included in sequencing and this analysis. Baby GERMS-SA, GBS-COP, KWTRP, and MLW also included *Klebsiella* cultured from cerebrospinal fluid (CSF) of participants. For the long-term prospective surveillance studies (KWTRP, MLW), isolates from all positive blood or CSF cultures were stored for future research. At KWTRP, all neonates had blood culture on admission and again if their clinical condition deteriorated. At MLW, cultures were performed for all neonates with clinical signs of sepsis or meningitis, temperature >37.5°C, or other signs of clinical deterioration.

For all studies, neonatal isolates identified as *Klebsiella*, which could later be revived for DNA extraction, were sequenced and those sequences that passed quality filters were included in this analysis (see inclusion criteria below). Details of microbiology, sequencing, and bioinformatics methods used in each study, including the quality-control criteria applied prior to sharing genome sequences for this analysis, have been reported previously [39] and are summarized in **S2 Table**. Briefly, all studies utilized Illumina platforms and assembled genomes using either SKESA v2.3.0 (MBIRA) or SPAdes (all other studies). Genome assemblies were analysed using Kleborate v3.0 [41] to confirm species, identify multi-locus sequence types (STs), antimicrobial resistance (AMR) and hypervirulence determinants, and to identify capsular (K) loci (KL) and O types using Kaptive v3.0 [42].

Inclusion and exclusion criteria

Inclusion criteria for individual samples from the studies were: *K. pneumoniae* isolated from the blood or CSF of a neonate (defined as 0-28 days post birth), between 2013 and 2023 inclusive. CSF isolates were included from three studies (KWTRP surveillance, n=5; GBS-COP, n=2; MLW Biobank, n=31). Repeat *K. pneumoniae* isolates from the same participant with the same KL were excluded, ensuring that each genome represents a unique infection

from an individual neonate (with the exception of MLW Biobank, for which archived isolates were not associated with patient identifiers thus precluding the exclusion of repeat isolates). Genome sequences identified as species other than *K. pneumoniae* or failing to meet the quality control criteria for assemblies (≤1,000 contigs and genome size 5–6.2 Mbp, as reported by Kleborate v3) were excluded. Additionally, study sites contributing fewer than 10 high-quality *K. pneumoniae* genomes that met the inclusion criteria were excluded (54 genomes from 12 sites), as it is not meaningful to estimate a fraction when the denominator is <10. Specifically, data were excluded from twelve sites that participated in multicenter studies (MBIRA, BARNARDS, DH, GBS) but yielded fewer than 10 high-quality *K. pneumoniae* genomes. Seven of these sites had <5 high-quality *K. pneumoniae* genomes each (no clusters as per the definition below); five sites had n=6-8 isolates each, 3 of which had a cluster. The reasons for low counts vary but are likely associated with differences in patient numbers as well as diagnostic stewardship and sensitivity. A flow diagram detailing sample inclusion is shown in **S1 Figure**, including available information on the number of samples that were not stored, could not be revived for DNA extraction, failed sequencing, or did not meet genome quality control thresholds for each contributing study.

Identification of transmission clusters

Pairwise single nucleotide variant (SNV) distances were calculated using Pathogenwatch, which enumerates differences in a library of 1,972 core genes (totalling 2,172,367 bp) [43]. Transmission clusters were defined within each study site based on both the pairwise genetic distances (≤10 SNVs) and temporal distances (≤4 weeks based on date of specimen collection) between isolates. The igraph v1.4.1 R package [44] was used to identify single-linkage transmission clusters by constructing an undirected graph from an edge list of isolate pairs. Each edge in the undirected graph represented a pairwise connection between isolates that were genetically similar (pairwise distance less than or equal to the specified genetic distance threshold), sampled within a specified temporal window (up to the specified

temporal distance threshold), and isolated from the same site. Distinct transmission clusters

were then defined as connected components of the resulting graph. This results in single-

linkage clusters, where each isolate is within the thresholds of both genetic and temporal

distance from at least one other isolate in the cluster, but pairs of isolates within the same

cluster may be separated by distances greater than the threshold. Therefore clusters can

include isolates cultured over any period, as long as the distances between consecutive

isolates in the cluster fall below the temporal threshold.

Estimation of cluster and transmission proportions

We estimated two key parameters – cluster proportion and transmission proportion – as

indices of the contribution of transmission to the burden of *K. pneumoniae* neonatal disease

in each neonatal care setting. The cluster proportion estimate was calculated as the number

of *K. pneumoniae* isolates in clusters, divided by the total number of culture-confirmed and

sequenced *K. pneumoniae*, for each site. The transmission proportion, on the other hand,

was a conservative estimate of the proportion of *K. pneumoniae* isolates that were

attributable to transmission. To estimate this, we excluded the first neonate in each cluster

as a potential index patient, and assumed that all other infections within clusters were due to

onward transmission in the unit. This almost certainly results in an underestimation of

infections attributable to transmission, as the index patient may have also acquired *K.*

pneumoniae from a contaminated source within the unit or an asymptomatically colonised

neonate. The transmission proportion estimate was thus calculated as below:

$$\frac{(total\ number\ of\ cluster\ isolates) - (number\ of\ index\ cases)}{total\ number\ of\ isolates}.$$

Sensitivity analyses

We conducted a sensitivity analysis to determine the impact of the choice of genetic distance

and temporal distance thresholds on the estimates of cluster proportion and transmission

proportion. The estimates were calculated and compared across a range of genetic distance

thresholds (range: 0–25 SNVs) and temporal distance thresholds (range: 1–52 weeks). We

also assessed how using different methods for calculating pairwise genetic distances

between all isolate pairs could impact the obtained estimates. To do this, we generated

reference-free SNV alignments of all genomes in the BARNARDS and SPINZ datasets using

the split k-mer analysis (SKA) method with SKA2 v0.4.1 [45,46]. A SKA index was first built

from the input assemblies using a k-mer size of 31, after which pairwise distances between

all genomes were calculated using the "distance" subcommand with a minimum frequency

threshold of 0.9 to include only core-genome SNVs. The cluster and transmission proportion

estimates were re-calculated using these SKA-derived SNV distances and compared to

those obtained using the Pathogenwatch core gene SNV distances.

Statistical analysis

All analyses and visualisations were performed using R v4.2.3 [47].

The methods for clustering infections, quantifying transmission, and exploring the sensitivity

of the estimates to selected thresholds (as described above) are implemented in a species-

agnostic Shiny web application (https://klebsiella.shinyapps.io/transmission_estimator/), with

source code available at https://github.com/klebgenomics/transmission_estimator (DOI:

10.5281/zenodo.17593948).

To assess heterogeneity of estimates between sites, for the multicentre studies BARNARDS

and MBIRA, we performed meta-analysis of proportions using a generalised linear mixed

model (GLMM) with a logit transformation to pool estimates of cluster proportion and

transmission proportion across all study sites. A random effects model was applied to

account for between-site variability, and 95% confidence intervals were computed using the

Clopper-Pearson method. Heterogeneity between sites was assessed visually using Forest

plots and quantitatively using the I^2 statistic. The meta-analysis was conducted using the

metaprop function of the meta v7.0.0 R package [48].

To identify facility characteristics associated with transmission, we performed pairwise two-

tailed binomial tests with Bonferroni correction, with facility-level data as categorical (facility

size, number of neonatal beds, availability of piped water) or binary (onsite availability of

neonatal surgical facilities) variables.

The proportions of isolates with extended-spectrum beta-lactamase (ESBL) and

carbapenemase genes were compared between clustered and non-clustered cases using

the Chi-squared test. To model different bacterial features (ESBL gene carriage,

carbapenemase gene carriage, ST, O type, K locus) and institutional factors (hospital site)

as potential predictors of transmission, we fitted logistic regression models in which each

introduction was treated as a single observation, with the outcome recorded as transmission

(cluster size ≥2) or no evidence of transmission (unclustered singleton case). For each

cluster, each predictor was assigned the consensus value for that cluster (e.g. if 3 of 4 cases

had ESBL gene/s detected, the cluster was recorded as ESBL-positive). Presence of ESBL

(Kleborate score ≥1) or carbapenemase (Kleborate score ≥2) genes were encoded as binary

variables. ST was encoded as a categorical variable, with one category per ST for commonly

transmitted STs (occurring in ≥3 clusters and ≥2 sites), and the reference category being the

group of all 158 'other STs' (49.2% in the reference category). O type was encoded as a

categorical variable, with the most common type, O1 (51.6%), as the reference category. K

locus was encoded as a categorical variable, with the top 10 K loci compared against 'other

K loci' as the reference category (n=70, 87.5% in the reference category). Models were fitted

using Firth's bias reduction method, implemented in the logistf package in R (v1.26.0). All

alternative models were compared using the likelihood ratio test, using the anova function in

base R.

Data availability

Sample-level data are described in **S3 Table** (dates are shown as year only, to protect participant privacy). Raw whole-genome sequence data were deposited by the originating study teams in INSDC databases, under the following BioProjects: BARNARDS, PRJEB33565; SPINZ, PRJEB46513; MLW, PRJEB42462; NIMBI-plus, PRJNA1168993; DH, PRJEB70311; Baby GERMS-SA, PRJNA796486 and PRJNA1282934; GBS-COP, PRJNA1175467; KWTRP, PRJNA1265413; MBIRA: PRJNA1274034, NeoBAC, PRJNA1265413. All input data and code required to reproduce the results, figures, and tables presented in this paper are available at https://github.com/klebgenomics/KlebNNS_transmission (DOI: 10.5281/zenodo.17591910). This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (**S1 Checklist**).

Results

Estimating transmission proportion

The study included 1,523 isolates from 27 sites in 13 countries, including Malawi (n=389), Zambia (n=304), Kenya (n=233), Ethiopia (n=125), Tanzania (n=58) and Rwanda (n=15) in Eastern Africa; Nigeria (n=50) and Ghana (n=25) in Western Africa; South Africa (n=214) and Botswana (n=29) in Southern Africa; India (n=34), Pakistan (n=30) and Bangladesh (n=17) in South Asia (**Table 1, S2 Figure**). Sample size per site ranged from 12 to 362 genomes, with dates of isolation spanning 26 to 537 weeks per site. Six sites included data from only one year. A majority of the isolates were from Eastern Africa (n=1124), followed by Southern Africa (n=243), South Asia (n=81), and Western Africa (n=75). See **Table 2** for characteristics of neonatal care facilities included in the study.

A total of 156 transmission clusters were identified across all sites, comprising 1,035 unique

infections (68.0%) (**S3 Figure**). The identified clusters spanned between 1 and 249 days

duration between the first and last cases (median: 14 days; interquartile range [IQR]: 6–28

days), with a median of 3 infections per cluster (range: 2–188, IQR: 2–5) (**S4 Table)**. Almost

half (73/156) of the clusters comprised only 2 infections. Excluding these 73 clusters as

potential coincidental isolation of similar but independently introduced strains rather than

nosocomial transmission, there were still 879 (57.7%) infections involved in 83 clusters

affecting at least 3 patients each (median cluster size, 5 cases). Sixteen clusters overlapped

either the beginning (n=7, cluster size: median = 3, range = 2–188) or the end (n=9, cluster

size: median = 3, range = 2–32) of the sampling periods in the respective sites, suggesting

that transmission may have been ongoing before sampling began or continued after

sampling ended.

The median estimates, across 27 sites, for cluster and transmission proportion were 53.3%

and 33.5%, respectively (**Figure 1**). Sensitivity analyses showed these estimates were

robust to the choice of thresholds and genetic distance estimation methods (**S4 Figure, S1**

Appendix). Cluster and transmission proportion estimates varied widely by site, ranging

from 0 to 93% and 0 to 87%, respectively (**Figure 1**). In 10 of the 27 sites (37%), at least half

of all infections were attributable to transmission, and in 14 sites (52%) at least a third of

cases were attributable to transmission. Across all sites, the median number of clusters

detected per site per year was three (IQR: 2–4, range: 0–13). Considering only clusters with

≥3 patients, we identified median one cluster per site per year (IQR: 1–3, range: 0–8).

Transmission proportions were heterogeneous within regions, although higher values were

estimated in Eastern Africa (median=65.0% [range: 29.6–93.5%], n=11 sites) compared with

Western Africa (40% [37.5–41.2%], n=3 sites) and South Asia (43.3% [23.5–88.2%], n=3

sites). Intermediate values were estimated in Southern Africa (median = 54.8% [0–77.3%],

n=10 sites).

(A) Cluster proportion

(B) Transmission proportion

Figure 1. Estimates of cluster and transmission proportion across sites.
(A) Cluster proportion **(B)** Transmission proportion. Plots show the point estimates (boxes) and 95% confidence intervals (horizontal bars) for each site. The median estimate is represented by the broken vertical line.

To determine whether differences in study design and sampling methodology contributed to

the heterogeneity observed between sites, we conducted two secondary meta-analyses

using data from two multi-site studies in our dataset (MBIRA and BARNARDS), each of

which used a consistent study protocol across multiple sites [5,34]. The pooled estimate of

transmission proportion across the seven BARNARDS sites was 26.1% (95% CI: 11.5–

49.0%, range: 0–79%) and there was substantial heterogeneity between sites (I^2 = 88.6%

[79.0%–93.8%]). The findings with the MBIRA dataset were similar, with a pooled

transmission proportion estimate of 37.0% (95% CI: 15.8–64.8%, range: 8–86%) and

significant heterogeneity (I^2 = 89.0% [78.8–94.3%] was observed across the six sites.

Notably, the lowest cluster proportion observed in both these studies was at the same

neonatal unit, sampled under different protocols at different time periods (BARNARDS 15A,

2016-2017 and MBIRA 15B, 2021), but yielding similar results each time (0 clusters out of 12

isolates, and 1 clustered pair out of 13 isolates, respectively). This suggests that the

observed heterogeneity in the full analysis is unlikely to be influenced by primary study

protocol differences alone, but may instead reflect variation in unmeasured factors such as

demographic, geographic and/or site-specific variations.

S5 Figure shows a comparison of cluster proportion across different sites based on

descriptive characteristics of the health facilities (summarised in **Table 2**). Notably facility

size and neonatal bed count were not associated with the number of *K. pneumoniae* isolates

per site (R^2 <0.01, p=0.993 and R^2 = 0.14, p=0.053, respectively using linear regression).

For example, the lowest cluster proportions were observed at site 15, which is one of the

largest neonatal units but as noted above had very few cases or clusters, potentially

because it is one of the better-resourced facilities (located in Cape Town, South Africa with

relatively strong microbiological diagnostics, surveillance and IPC capacity). Facilities with

only occasional availability of piped water (two in Ethiopia, one in Zambia) had a higher

proportion of cases in clusters (87.7% [range: 64.5–89.4%]) than those where piped water

was reported as being available most of the time (n=6; 42.5% [23.5–74.0%]; p<0.001 using

Binomial test) or always (n=18; 52.9% [0–93.5%]; p<0.001 using Binomial test) (**S5 Figure**).

District hospitals with no surgical facilities onsite (two in Kenya, one in India) also had a

higher proportion of cases in clusters (88.2% [65.0–93.5%]) than hospitals with surgical

facilities available onsite (n=24, 49.9% [0–89.4%], p<0.001 using Binomial test).

Genomic characteristics of transmitted *K. pneumoniae*

A total of 172 distinct *K. pneumoniae* STs were identified amongst the included isolates (**S5**

Table). Of these, 57 STs were associated with at least one transmission cluster. We defined

commonly transmitted STs as those that were identified in ≥3 transmission clusters in two or

more sites. Fourteen STs met this definition (**Figure 2**), and these made up 63.8%

(n=972/1523) of all infections, including 71.8% (n=743/1035) of clustered infections and

46.9% (n=229/488) of unclustered infections. Twelve of the 14 commonly transmitted STs

were detected in ≥3 countries each, however ST152 and ST25 were each identified in just

one country (South Africa and Malawi, respectively). Most of the 14 STs were associated

with clusters at Malawi site 6B (see **Figure 2B**), which is not unexpected given this is the

largest dataset and originates from seven years of routine blood culture surveillance;

however, besides ST25, all common STs associated with clusters at this site were also

associated with clusters at multiple other sites. The 14 commonly transmitted STs were

responsible for most large clusters with ≥15 cases (n=6/10 clusters; 60%; **Figure 2D**),

although four large clusters were caused by rarely transmitting STs (ST6775, n=29; ST37,

n=26; ST2004, n=20; and ST1414, n=17). **Figure 3** shows, for each ST, the number of

unique introductions (treating each cluster or singleton as a unique strain 'introduction' in a

neonatal ward) vs the number of infection clusters. Across all STs, the mean fraction of

introductions resulting in detected infection clusters was 15.3%, and this fraction was

significantly higher among the 14 commonly transmitted STs compared to the other 158 STs

(mean 33.1% vs 13.8%, Chi-squared test p<0.001).

Figure 2. Commonly transmitted *K. pneumoniae* STs.
(A) Transmission profile showing number of clusters, number of singleton cases, total number of sites the STs were detected, number of sites where the STs were part of transmission clusters, their adjusted odds ratios compared to other STs in a logistic regression model to assess association with transmission, and corresponding p-values (columns from left to right). P-values for STs with a significant association with transmission are formatted in bold (see Methods for details of the logistic regression analysis). **(B)** Site distribution of cluster isolates. Points are coloured to indicate geographical region and sized to indicate number of clustered isolates per site. **(C)** Resistance distribution (proportion) of cluster isolates. Resistance scores are as reported by Kleborate based on the presence or absence of extended-spectrum beta-lactamase genes (ESBL), carbapenemase genes (Carb), and/or colistin resistance determinants (Col). **(D)** ST composition of large clusters. Points are coloured to indicate the 14 commonly transmitted STs and sized to indicate the number of isolates, as per the figure legend.

Figure 3. Transmission probability of individual STs
(A) Distribution of the fraction of strain introductions resulting in clusters, for individual STs. Bars are coloured to indicate commonly transmitted STs (per the panel legend), defined as STs that were identified in ≥3 transmission clusters in two or more sites. **(B)** Number of unique introductions vs number of clusters, for individual STs. Points are sized to indicate the number of sites where clustered isolates were detected for each ST, and coloured to indicate commonly transmitted STs significantly associated with transmission in the logistic regression model. The dashed line shows y=x, along which the number of unique introductions is equal to the number of clusters. The solid line represents a linear regression line of best fit through the origin (slope 0.28, R^2=0.920). **(C)** Fraction of clusters and singletons with ESBL and/or carbapenemase. Points are plotted for the 57 STs involved in clusters, and coloured to indicate commonly transmitted STs significantly associated with transmission. ST: sequence type. ESBL/CP: extended-spectrum beta-lacatamase or carbapenemase gene carriage (Kleborate resistance score ≥ 1).

The majority of isolates (n=1384/1523, 90.9%) carried an ESBL or carbapenemase gene.

Clusters were more likely to carry ESBL (94.2% of clusters (n=147/156) vs 81.8% of

singletons (n=399/488), p<0.001) or carbapenemase genes (19.9% of clusters (n=31/156)

vs 10.2% of singletons (n=50/488), p=0.0025) (**S6 Table**). In a logistic regression model for

transmission, treating each cluster or singleton as a unique strain 'introduction' in a neonatal

ward, and defining the outcome for each introduction as either evidence of transmission (i.e.

cluster of size ≥2) or no evidence of transmission (i.e. a singleton unclustered case),

transmission was significantly positively associated with carriage of ESBL genes (adjusted

odds ratio, aOR = 2.84 [95% CI: 1.45–5.57], p<0.001) or carbapenemase genes (aOR =

1.81 [95% CI: 1.10–2.98], p=0.02) (**S7 Table**). Including Site as a covariate improved model

fit (p=0.05 using likelihood ratio test), but did not substantially alter the effect estimates for

ESBLs (aOR = 2.48 [95% CI: 1.26–4.90], p=0.006) or carbapenemases (aOR = 2.08 [95%

CI: 1.04–4.14], p=0.04).

It is challenging to tease apart the effect of AMR from the effect of lineage, as certain

lineages may appear more likely to cause detectable infection clusters due to their

resistance genes (if AMR is a driver of transmission and/or infection), or strains with

resistance genes might appear more likely to cause detectable infection clusters due to their

association with particular genetic lineages (if non-AMR-related lineage-associated

differences drive transmission and/or infection). The 14 commonly transmitted STs showed a

significantly higher rate of ESBL gene carriage (amongst singleton infections or deduplicated

clusters) compared to the other 158 STs (94.2% (n=308/327) vs 75.1% (n=238/317),

p<0.0001), although there was no significant difference in carbapenemase gene carriage

rates (14.1% (n=46/327) vs 11% (n=35/317), p=0.30) (**S8 Table**). Amongst the 14 most

common transmission STs, nearly all (n=728/743; 98%) of the clustered isolates carried at

least one ESBL or carbapenemase gene, compared with 93% (n=213/229) amongst

singleton isolates of these STs (**Figure 3C**). Adding ST (as a categorical variable with each

of the 14 common STs as unique categories, compared to all other STs as the reference

category) to the logistic regression model with ESBL, carbapenemase and Site did not

improve the model (p=0.226), and had little impact on the estimated effects of ESBL (aOR =

2.16 [95% CI: 1.08–4.32], p=0.03) and carbapenemase (aOR = 2.03 [95% CI: 1.01–4.08],

p=0.05), and only two STs were significantly independently associated with transmission

(ST17, aOR = 2.24 [95% CI: 1.11–4.52], p=0.03 and ST1741, aOR = 20.9 [95% CI: 1.2–

363.7], p=0.01).

As K and O antigens have been proposed as potential vaccine targets, we explored their

prevalence (based on genomic predictions) and association with transmission in our dataset.

Six unique O serogroups were predicted (see **S9 Table**), the majority being O1 (n=332/644,

51.6%) or O2 (n=158/644, 24.5%), which were common amongst both clusters and

singletons (51.3% vs 51.6%, respectively for O1, 26.9% vs 23.8% for O2). Including O types

in the transmission model with ESBL and carbapenemase genes, with or without ST and/or

Site, did not improve model fit (p>0.2 using likelihood ratio test), and no O types were

significant in any models (see **S7 Table**).

Eighty distinct K loci were detected. Forty-three K loci were found in isolates associated with

transmission clusters, and 39 of these were also identified in singleton isolates (**S10 Table**).

Distinct K loci were associated with specific STs, making it difficult to tease apart the effect

of K antigens from strain background. For example, KL102, which was the most common K

locus associated with transmission, was closely associated with ST307: 95% (n=241/253) of

KL102 isolates from transmission clusters were ST307, and ST307 accounted for 83%

(n=15/18) of KL102 clusters detected. Similarly, 79% (n=42/53) of KL25 cluster isolates

belonged to either ST17 (n=33, 62%) or ST607 (n=9, 17%). Including the top 10 most

common K loci in the transmission model together with ESBL and carbapenemase genes,

with or without ST and/or Site, did not improve the model fit (p>0.38 using likelihood ratio

test), although KL62 was significantly positively associated with transmission (aOR 4.77

[95% CI, 1.30–17.49], p=0.025) in the model with ESBL and carbapenemase genes, ST, and

Site. KL62 was associated with 12 clusters (n=26 isolates) out of 34 introductions (n=6

different STs) across 16 sites.

Discussion

Neonatal sepsis caused by *K. pneumoniae* infection is a significant health challenge in Africa

and Asia with disproportionately high incidence and mortality rates. Our analysis estimated

that over half of all neonatal sepsis cases at the included sites were within transmission

clusters, with a median 33.5% of all cases attributable to nosocomial transmission (**Figure**

1).

Transmission analyses typically require detailed data on patient admission, ward

movements, and recent healthcare exposures in addition to pathogen sequence data; these

are hard to standardise across studies and thus between-study comparisons or meta-

analyses are challenging. Here, however, we used studies in which all consecutive neonates

with sepsis in a defined physical unit were sampled and the resulting isolates sequenced,

allowing us to undertake a standardised clustering analysis based on genetic and temporal

distances within each unit, applied to data collected across 10 unique studies.

Furthermore, as our goal was to estimate the fraction of cases linked to others in

transmission clusters, rather than trying to resolve specific transmission chains or pathways,

our approach was robust to changes in distance thresholds (see **S4 Figure, S1 Appendix**).

This is because lowering clustering thresholds tends to break larger single-linkage clusters

into smaller ones (which has no impact on the overall fraction included in clusters), rather

than breaking clusters into completely un-linked singleton cases. Variations in genetic and

temporal distance thresholds have a greater impact in real-time outbreak investigations,

where the goal is to identify specific transmission events and sources. In that context, the

choice of thresholds can be adjusted to achieve a desired preference for sensitivity or

specificity in cluster detection. Interestingly, previous studies have proposed whole-genome

SNV cutoffs of between 21 and 25 for identifying *K. pneumoniae* nosocomial transmission,

which is equivalent to the 10 Pathogenwatch core-gene SNV threshold used in our analysis

[18,49,50].

As with other opportunistic pathogens frequently implicated in hospital-acquired infections,

reservoirs and transmission routes for *K. pneumoniae* infection are abundant in the hospital

environment, and genomics has been used to resolve specific sources in several studies.

These include transmission through direct contact with contaminated surfaces, sinks,

cleaning supplies, medical devices, and healthcare personnel [51–55]. Neonates are at high

risk of hospital-acquired infections due to their naive or compromised immune systems,

exposure through invasive procedures in critical care settings, repeated handling by multiple

caregivers, and long hospital admissions [56,57]. While our study indicates a high impact of

IPC deficiencies in neonatal units in LMICs, identifying suitable solutions will require better

understanding of risk factors, transmission routes, and sources of contamination. The

solutions will also require appropriate testing in clinical trials or complex interventions and

subsequently funding for implementation at scale.

We observed a high diversity of *K. pneumoniae* lineages (172 unique STs) implicated in

neonatal sepsis cases across hospitals in Asia and Africa (**S5 Table**), consistent with

previous reports of a highly diverse etiology of *K. pneumoniae*-associated neonatal sepsis

[5,22]. A third of these STs were part of at least one transmission cluster, among which 14

STs were identified as commonly transmitted, occurring in ≥3 clusters and ≥2 sites.

However, most of these were also common among singleton isolates and accordingly our

logistic regression analysis indicated only two of these STs were significantly associated with

transmission clusters, compared with other STs. This finding is consistent with the

hypothesis that many different STs can become common causes of transmission clusters,

either because they possess traits that render them particularly fit for transmission in the

hospital setting, or simply because they are more prevalent (e.g. as gut colonisers in the

community) and therefore have greater stochastic opportunity due to more frequent

introductions to the hospital setting. Importantly, the signal of transmission we are exploring

in this study – detection as a cluster of clinical infections – is the product of multiple factors

including colonisation potential, virulence, and environmental survival, and we are unable to

tease apart the relative contributions of these different factors in determining which strains

are identified frequently in clusters. Notably, many of the 14 commonly transmitted STs

identified here, including ST11, ST14, ST15, ST17, ST29, ST101 and ST307 are recognised

high-risk clones, widely implicated in multidrug-resistant (MDR) hospital-acquired infections

worldwide [58–60], consistent with our observations. ST39 has been reported less

frequently, but is also disseminating rapidly worldwide, including in Africa, where it has been

implicated in MDR neonatal outbreaks in The Gambia and Malawi [22,28,61].

The overall high rates of AMR among the *K. pneumoniae* isolates (clustered and singleton)

in this study (see **S6 Table**) is concerning, as a high degree of resistance is known to be

associated with higher rates of nosocomial spread [18,62], a finding that was corroborated in

our analysis. We found that cluster cases had significantly higher rates of ESBL and

carbapenemase gene carriage compared to single cases, and isolates belonging to the 14

most commonly transmitted STs more frequently carried ESBL genes compared to other

STs (**S6 Table, S8 Table**). Carbapenemase and ESBL gene carriage were also

independently associated with transmission in the multivariable regression analysis (**S7**

Table). It is likely that these AMR phenotypes also contribute to case detection, as strains

resistant to empirical therapy are more likely to be present in the blood at sufficient quantities

to be detected by blood culture, making it more likely for transmitted AMR strains to result in

cluster detection than transmitted susceptible strains.

While AMR almost certainly plays a role in the successful persistence of *K. pneumoniae*

clones within the hospital setting, other potential factors such as survival on environmental

surfaces and colonisation ability are less well characterised [63]. For instance, ST17, the

most commonly transmitted ST in this study, was recently demonstrated to colonise the

gastrointestinal tracts of children for up to 2 years, a factor that may contribute to its

increased transmissibility [64]. ST307 is frequently associated with outbreaks and believed

to be adapted to the hospital environment where it can persist for extended periods and

rapidly spread among patients [25,63,65]. In this study, ST307 was responsible for the

largest identified cluster (involving 188 neonates over a 32-week period at a hospital in

Zambia), and 14 other clusters across 8 sites in Kenya, Malawi, Rwanda, Zambia, South

Africa and Ghana. However, ST307 was also detected in 43 singleton infections, and only

26% (n=15/58) of detected ST307 introductions in the neonatal units were associated with

transmission clusters (similar to the background rate observed across 158 non-commonly

transmitted STs). This suggests that the frequency of ST307 among hospital outbreaks may

reflect a generally high prevalence (i.e., as a gut coloniser) resulting in greater opportunity, in

combination with or instead of a specific propensity for transmission in the hospital setting.

Further research is needed to determine if specific STs have enhanced risk for transmission

once introduced into the hospital setting, and to elucidate potential factors that contribute to

their success as hospital-acquired opportunistic pathogens.

In summary, our findings demonstrate the need to improve IPC practices in neonatal care

settings in LMICs, and highlight the potential benefits of genomic surveillance of *K.*

pneumoniae and other pathogens to assess IPC impacts and/or to support real-time

outbreak detection and investigation. Limiting horizontal transmission through improved IPC

measures is undoubtedly a crucial prevention strategy that could prevent a significant

proportion of neonatal sepsis caused by *K. pneumoniae* and other pathogens, and curb the

spread of AMR. Studies have shown that *K. pneumoniae* outbreaks in neonatal units can in

principle be effectively controlled by implementing simple IPC measures like contact

precautions and improved hand hygiene [21,28,31]. However, to be truly effective in

reducing overall disease burden, these measures need to be proactive, rather than reactive,

and be integrated into routine practice. The implementation of consistent and effective IPC

measures in resource limited settings remains challenging due to resource constraints,

inadequate infrastructure, limited cleaning supplies, understaffing, and limited access to

training [66,67]. Whilst this analysis was not suited to probing the determinants of variation in

transmission rates, we did find that the three facilities with limited access to piped water

displayed high cluster proportions, highlighting the challenges faced in some settings and

their impact on hygiene and patient safety. In contrast, the lowest cluster proportions and the

lowest isolate counts were observed in consecutive studies at the same large tertiary care

hospital in South Africa, which is comparatively well resourced in terms of infrastructure and

staffing. Simplified IPC models tailored to resource-constrained settings and focused on

training, improved cleaning, and hand hygiene have been proposed and demonstrated to

reduce the incidence of neonatal sepsis and mortality [31]. However it is clear that to be

effective, such measures must be supported by sustained investment in infrastructure,

equipment, staff and training [68]. In addition, to maximise their effectiveness, IPC

implementation should be periodically assessed using suitable assessment tools and

reviewed as necessary [69–71]. IPC strategies must also be supported by expanding access

to blood culture facilities [72,73], accurate diagnostics and robust clinical and microbiological

surveillance [74], ideally incorporating whole-genome sequencing, to enable prompt

detection of infections, precise transmission tracking, and timely institution of control

measures.

Additionally, our findings also have implications for clinical management. WHO guidelines for

empirical treatment of neonatal sepsis (third-generation cephalosporins plus gentamicin [75])

are likely to be ineffective against the vast majority of *K. pneumoniae* characterised in this

study, which mostly carried ESBL genes, consistent with recent reports from NeoOBS and

other studies [11,76]. Access to blood culture facilities, robust clinical diagnostics and

susceptibility testing is essential to monitor AMR and update local syndromic guidelines, as

is improving access to effective antibiotics in all settings.

Limitations

The major limitation of this study is the unavailability of standardised clinical and patient-level

data across the included sites, which precludes a more in-depth investigation of potential

transmission routes and overall transmission dynamics, and the delineation of infections

based on the timing of disease onset relative to admission (which can be an indicator of

hospital- vs community-acquired infection) or to date of birth (early vs late onset sepsis).

Notably, component studies with sufficient data to investigate onset relative to admission

showed that clustered cases often had rapid onset following admission to the neonatal unit,

and one study linked rapid-onset disease to contaminated intravenous fluids, confirming

nosocomial transmission [32,37]. This suggests that the timing of symptom onset following

admission is not a reliable indicator of hospital- vs community-acquired disease in these

settings, even if such data were available. This study also did not include matched maternal

data to investigate vertical transmission as an alternative transmission route, albeit it is

important to note that studies suggest that this is unlikely to play a significant role in *K.*

pneumoniae neonatal sepsis [5,77]. Another limitation was the reliance on *post hoc*

collaborator-elicited facility-level data rather than systematically collected data to explore the

potential causes of variation in transmission rates across the different hospitals. Further

studies using tailored, prospectively collected data are needed to explore site-specific factors

that may influence transmission risk. Also, as this study predominantly comprised tertiary-

level healthcare facilities, our findings may not be generalisable to lower-tier healthcare

facilities.

The attributable transmission fraction observed in our analysis (median = 33.5%) is likely an

underestimate due to the conservative nature of our transmission proportion definition. Our

assumption that the 'index cases' were not attributable to transmission discounts the very

likely possibility that they themselves acquired their infection from the same source as the

subsequent cases (e.g., via contaminated equipment or the hands of a carer). The cluster

proportion is also likely biased towards underestimation due to missed cases (including

colonisation episodes that did not result in a culture-confirmed infection), excluded cases

(e.g., children aged >28 days in the same neonatal units), or cases that were acquired in the

neonatal unit but not clustered with another sequenced isolate (e.g. a contaminated source

may lead to colonisation or even disease in multiple neonates, of which only one individual

case of invasive disease is detected). Given these underestimations, even the cluster

proportion (median = 53.3%) probably provides a conservative estimate of the true fraction

of sepsis cases amenable to prevention with improved IPC measures.

Acknowledgments

We thank the participants and their families in all the contributing studies, and the clinical

and laboratory staff involved in collection and processing of relevant samples and isolates.

This work was supported by the MASSIVE HPC facility (www.massive.org.au). We would

also like to acknowledge the expert support of the sequencing and computational genomics

teams at the CHOP Microbiome Core (Philadelphia), International Livestock Research

Institute (Nairobi), Kilimanjaro Clinical Research Institute (Moshi), Neuberg Center for

Genomic Medicine (Ahmedabad), NICD (Johannesburg), Quadram Institute (Norwich),

Wellcome Centre for Human Genetics (Oxford), and Wellcome Sanger Institute

(Cambridge); and the BARNARDS microbiology and genomics team at Cardiff University.

References

1. World Health Organization. Newborn mortality. 2024 [cited 8 Aug 2024]. Available: https://www.who.int/news-room/fact-sheets/detail/newborn-mortality

2. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child. 2021;106: 745–752. doi:10.1136/archdischild-2020-320217

3. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395: 200–211. doi:10.1016/S0140-6736(19)32989-7

4. Okomo U, Akpalu ENK, Doare KL, Roca A, Cousens S, Jarde A, et al. Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. Lancet Infect Dis. 2019;19: 1219–1234. doi:10.1016/S1473-3099(19)30414-1

5. Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat Microbiol. 2021;6: 512–523. doi:10.1038/s41564-021-00870-7

6. Duggan HL, Chow SSW, Austin NC, Shah PS, Lui K, Tan K, et al. Early-onset sepsis in very preterm neonates in Australia and New Zealand, 2007-2018. Arch Dis Child Fetal Neonatal Ed. 2023;108: 31–37. doi:10.1136/archdischild-2021-323243

7. Cailes B, Kortsalioudaki C, Buttery J, Pattnayak S, Greenough A, Matthes J, et al. Epidemiology of UK neonatal infections: the neonIN infection surveillance network. Arch Dis Child Fetal Neonatal Ed. 2018;103: F547–F553. doi:10.1136/archdischild-2017-313203

8. Sands K, Spiller OB, Thomson K, Portal EAR, Iregbu KC, Walsh TR. Early-Onset Neonatal Sepsis in Low- and Middle-Income Countries: Current Challenges and Future Opportunities. Infect Drug Resist. 2022;15: 933–946. doi:10.2147/IDR.S294156

9. Arvay ML, Shang N, Qazi SA, Darmstadt GL, Islam MS, Roth DE, et al. Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study. Lancet Glob Health. 2022;10: e1289–e1297. doi:10.1016/S2214-109X(22)00244-3

10. Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016;4: e752–e760. doi:10.1016/S2214-109X(16)30148-6

11. Russell NJ, Stöhr W, Plakkal N, Cook A, Berkley JA, Adhisivam B, et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). PLOS Med. 2023;20: e1004179. doi:10.1371/journal.pmed.1004179

12. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, et al.

Access to effective antimicrobials: a worldwide challenge. The Lancet. 2016;387: 168–175. doi:10.1016/S0140-6736(15)00474-2

13. Li G, Bielicki JA, Ahmed ASMNU, Islam MS, Berezin EN, Gallacci CB, et al. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child. 2020;105: 26–31. doi:10.1136/archdischild-2019-316816

14. Hernandez-Alonso E, Bourgeois-Nicolaos N, Lepainteur M, Derouin V, Barreault S, Waalkes A, et al. Contaminated Incubators: Source of a Multispecies Enterobacter Outbreak of Neonatal Sepsis. Microbiol Spectr. 2022;10: e00964-22. doi:10.1128/spectrum.00964-22

15. Frank Wolf M, Abu Shqara R, Naskovica K, Zilberfarb IA, Sgayer I, Glikman D, et al. Vertical Transmission of Extended-Spectrum, Beta-Lactamase-Producing Enterobacteriaceae during Preterm Delivery: A Prospective Study. Microorganisms. 2021;9: 506. doi:10.3390/microorganisms9030506

16. Kuitunen I, Kekki M, Renko M. Intrapartum azithromycin to prevent maternal and neonatal sepsis and deaths: A systematic review with meta-analysis. BJOG Int J Obstet Gynaecol. 2024;131: 246–255. doi:10.1111/1471-0528.17655

17. Dramowski A, Aucamp M, Beales E, Bekker A, Cotton MF, Fitzgerald FC, et al. Healthcare-Associated Infection Prevention Interventions for Neonates in Resource-Limited Settings. Front Pediatr. 2022;10: 919403. doi:10.3389/fped.2022.919403

18. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4: 1919–1929. doi:10.1038/s41564-019-0492-8

19. Freeman JT, Nimmo J, Gregory E, Tiong A, De Almeida M, McAuliffe GN, et al. Predictors of hospital surface contamination with Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: patient and organism factors. Antimicrob Resist Infect Control. 2014;3: 5. doi:10.1186/2047-2994-3-5

20. Zhang X, Li X, Wang M, Yue H, Li P, Liu Y, et al. Outbreak of NDM-1-Producing Klebsiella pneumoniae Causing Neonatal Infection in a Teaching Hospital in Mainland China. Antimicrob Agents Chemother. 2015;59: 4349–4351. doi:10.1128/AAC.03868-14

21. Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, Valderrama Márquez IA, Garzón Aguilar MI, Martinez de la Barrera L, et al. Outbreak of NDM-1-Producing Klebsiella pneumoniae in a Neonatal Unit in Colombia. Antimicrob Agents Chemother. 2013;57: 1957–1960. doi:10.1128/aac.01447-12

22. Heinz E, Pearse O, Zuza A, Bilima S, Msefula C, Musicha P, et al. Longitudinal analysis within one hospital in sub-Saharan Africa over 20 years reveals repeated replacements of dominant clones of Klebsiella pneumoniae and stresses the importance to include temporal patterns for vaccine design considerations. Genome Med. 2024;16: 67. doi:10.1186/s13073-024-01342-3

23. Frenk S, Rakovitsky N, Temkin E, Schechner V, Cohen R, Kloyzner BS, et al. Investigation of Outbreaks of Extended-Spectrum Beta-Lactamase-Producing Klebsiella Pneumoniae in Three Neonatal Intensive Care Units Using Whole Genome Sequencing. Antibiotics. 2020;9: 705. doi:10.3390/antibiotics9100705

24. Cornick J, Musicha P, Peno C, Seager E, Iroh Tam P-Y, Bilima S, et al. Genomic
investigation of a suspected Klebsiella pneumoniae outbreak in a neonatal care unit in
sub-Saharan Africa. Microb Genomics. 2021;7: 000703. doi:10.1099/mgen.0.000703

25. Magobo RE, Ismail H, Lowe M, Strasheim W, Mogokotleng R, Perovic O, et al.
Outbreak of NDM-1– and OXA-181–Producing Klebsiella pneumoniae Bloodstream
Infections in a Neonatal Unit, South Africa. Emerg Infect Dis. 2023;29: 1531–1539.
doi:10.3201/eid2908.230484

26. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-
acquired neonatal infections in developing countries. The Lancet. 2005;365: 1175–
1188. doi:10.1016/S0140-6736(05)71881-X

27. Mukherjee S, Mitra S, Dutta S, Basu S. Neonatal Sepsis: The Impact of Carbapenem-
Resistant and Hypervirulent Klebsiella pneumoniae. Front Med. 2021;8: 634349.
doi:10.3389/fmed.2021.634349

28. Okomo U, Senghore M, Darboe S, Bojang E, Zaman SMA, Hossain MJ, et al.
Investigation of sequential outbreaks of Burkholderia cepacia and multidrug-resistant
extended spectrum β-lactamase producing Klebsiella species in a West African tertiary
hospital neonatal unit: a retrospective genomic analysis. Lancet Microbe. 2020;1:
e119–e129. doi:10.1016/S2666-5247(20)30061-6

29. Meiring S, Mashau R, Magobo R, Perovic O, Quan V, Cohen C, et al. Study protocol for
a population-based observational surveillance study of culture-confirmed neonatal
bloodstream infections and meningitis in South Africa: Baby GERMS-SA. BMJ Open.
2022;12: e049070. doi:10.1136/bmjopen-2021-049070

30. Egbe FN, Cowden C, Mwananyanda L, Pierre C, Mwansa J, Lukwesa Musyani C, et al.
Etiology of Bacterial Sepsis and Isolate Resistance Patterns in Hospitalized Neonates
in Zambia. Pediatr Infect Dis J. 2023;42: 921–926.
doi:10.1097/INF.0000000000004008

31. Mwananyanda L, Pierre C, Mwansa J, Cowden C, Localio AR, Kapasa ML, et al.
Preventing Bloodstream Infections and Death in Zambian Neonates: Impact of a Low-
cost Infection Control Bundle. Clin Infect Dis. 2019;69: 1360–1367.
doi:10.1093/cid/ciy1114

32. Phillips LT, Bates M, Coffin SE, Foster-Nyarko E, Kapasa M, Machona S, et al.
Transmission dynamics of Klebsiella pneumoniae in a neonatal intensive care unit in
Zambia before and after an infection control bundle. PLOS Glob Public Health. 2026;6:
e0005965. doi:10.1371/journal.pgph.0005965

33. Shuping L, Ismail H, Mashau R, Kwenda S, Holt KE, Magobo RE, et al. Enhanced
detection of neonatal invasive infection clusters in South Africa using epidemiological
and genomic surveillance data. medRxiv; 2025. p. 2025.11.10.25339895.
doi:10.1101/2025.11.10.25339895

34. Aiken AM, Rehman AM, de Kraker ME, Madrid L, Kebede M, Labi A-K, et al. Mortality
associated with third-generation cephalosporin resistance in Enterobacterales
bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective
cohort study. Lancet Infect Dis. 2023;23: 1280–1290. doi:10.1016/S1473-
3099(23)00233-5

35. Jain K, Kumar V, Plakkal N, Chawla D, Jindal A, Bora R, et al. Multidrug-resistant

sepsis in special newborn care units in five district hospitals in India: a prospective
cohort study. Lancet Glob Health. 2025;13: e870–e878. doi:10.1016/S2214-
109X(24)00564-3

36.   Olwagen CP, Izu A, Khan S, Van der Merwe L, Dean NJ, Mabena FC, et al. Genomic
relatedness of colonizing and invasive disease Klebsiella pneumoniae isolates in South
African infants. Sci Rep. 2025;15: 8043. doi:10.1038/s41598-025-92517-4

37.   Strysko J, Hu W, Mochankana K, John-Thubuka J, Zankere T, Gopolang B, et al. Using
Genomic and Traditional Epidemiologic Approaches to Define Complex Transmission
Pathways of Klebsiella pneumoniae Infection in a Neonatal Unit in Botswana, 2022–
2023. medRxiv; 2025. p. 2025.11.06.25339637. doi:10.1101/2025.11.06.25339637

38.   Amulele AV, Orindi B, Ndumba ML, Tigoi C, Omuoyo D, Kahindi E, et al. Genomic
epidemiology of Klebsiella pneumoniae neonatal and infant sepsis in Kenyan hospitals.
medRxiv; 2025. p. 2025.10.30.25339129. doi:10.1101/2025.10.30.25339129

39.   Stanton TD, Keegan SP, Abdulahi JA, Amulele AV, Bates M, Heinz E, et al. Distribution
of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and
South Asia: A meta-analysis of genome-predicted serotype prevalence to inform
potential vaccine coverage. PLOS Med. 2026;23: e1004879.
doi:10.1371/journal.pmed.1004879

40.   United Nations Statistics Division. Standard Country or Area Codes for Statistical Use
(M49). [cited 2 Feb 2026]. Available: https://unstats.un.org/unsd/methodology/m49/

41.   Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic
surveillance framework and genotyping tool for Klebsiella pneumoniae and its related
species complex. Nat Commun. 2021;12: 4188. doi:10.1038/s41467-021-24448-3

42.   Stanton TD, Hetland MAK, Löhr IH, Holt KE, Wyres KL. Fast and accurate in silico
antigen typing with Kaptive 3. Microb Genomics. 2025;11: 001428.
doi:10.1099/mgen.0.001428

43.   Argimón S, David S, Underwood A, Abrudan M, Wheeler NE, Kekre M, et al. Rapid
Genomic Characterization and Global Surveillance of Klebsiella Using Pathogenwatch.
Clin Infect Dis. 2021;73: S325–S335. doi:10.1093/cid/ciab784

44.   Csardi G, Nepusz T. The igraph software package for complex network research.
InterJournal. 2006;Complex Systems: 1695.

45.   Harris SR. SKA: Split Kmer Analysis Toolkit for Bacterial Genomic Epidemiology.
bioRxiv; 2018. p. 453142. doi:10.1101/453142

46.   Derelle R, Wachsmann J von, Mäklin T, Hellewell J, Russell T, Lalvani A, et al.
Seamless, rapid and accurate analyses of outbreak genomic data using Split K-mer
Analysis (SKA). bioRxiv; 2024. p. 2024.03.25.586631. doi:10.1101/2024.03.25.586631

47.   R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
Austria: R Foundation for Statistical Computing; 2023. Available: https://www.R-
project.org/

48.   Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical
tutorial. Evid Based Ment Health. 2019;22: 153–160. doi:10.1136/ebmental-2019-
300117

49. Foster-Nyarko E, Cottingham H, Wick RR, Judd LM, Lam MMC, Wyres KL, et al.
Nanopore-only assemblies for genomic surveillance of the global priority drug-resistant
pathogen, Klebsiella pneumoniae. Microb Genomics. 2023;9: 000936.
doi:10.1099/mgen.0.000936

50. Gorrie CL, Mirčeta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al.
Gastrointestinal Carriage Is a Major Reservoir of Klebsiella pneumoniae Infection in
Intensive Care Patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65: 208–215.
doi:10.1093/cid/cix270

51. Regev-Yochay G, Margalit I, Smollan G, Rapaport R, Tal I, Hanage WP, et al. Sink-
traps are a major source for carbapenemase-producing Enterobacteriaceae
transmission. Infect Control Hosp Epidemiol. 2024;45: 284–291.
doi:10.1017/ice.2023.270

52. Nakamura I, Yamaguchi T, Miura Y, Watanabe H. Transmission of extended-spectrum
β-lactamase-producing Klebsiella pneumoniae associated with sinks in a surgical
hospital ward, confirmed by single-nucleotide polymorphism analysis. J Hosp Infect.
2021;118: 1–6. doi:10.1016/j.jhin.2021.08.013

53. Chapman P, Forde BM, Roberts LW, Bergh H, Vesey D, Jennison AV, et al. Genomic
Investigation Reveals Contaminated Detergent as the Source of an Extended-
Spectrum-β-Lactamase-Producing Klebsiella michiganensis Outbreak in a Neonatal
Unit. J Clin Microbiol. 2020;58: 10.1128/jcm.01980-19. doi:10.1128/jcm.01980-19

54. Galdys AL, Marsh JW, Delgado E, Pasculle AW, Pacey M, Ayres AM, et al.
Bronchoscope-associated clusters of multidrug-resistant Pseudomonas aeruginosa and
carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2019;40:
40–46. doi:10.1017/ice.2018.263

55. Pearse O, Lester R, Zuza A, Mangochi H, Siyabu P, Tewesa E, et al. Extended-
Spectrum Beta-Lactamase Klebsiella pneumoniae on a Malawian neonatal unit is
amplified by neonates and transmitted by maternal hands, cots and ward surfaces.
medRxiv; 2025. p. 2025.08.13.25333346. doi:10.1101/2025.08.13.25333346

56. Coffin SE, Zaoutis TE. HealthCare–Associated Infections in the Nursery. Infect Dis
Fetus Newborn. 2011; 1126–1143. doi:10.1016/B978-1-4160-6400-8.00035-3

57. Collins AS. Preventing Health Care–Associated Infections. In: Hughes RG, editor.
Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Rockville (MD):
Agency for Healthcare Research and Quality (US); 2008. Available:
http://www.ncbi.nlm.nih.gov/books/NBK2683/

58. Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat
Rev Microbiol. 2020;18: 344–359. doi:10.1038/s41579-019-0315-1

59. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major
worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41:
252–275. doi:10.1093/femsre/fux013

60. Wyres KL, Hawkey J, Hetland MAK, Fostervold A, Wick RR, Judd LM, et al.
Emergence and rapid global dissemination of CTX-M-15-associated Klebsiella
pneumoniae strain ST307. J Antimicrob Chemother. 2019;74: 577–581.
doi:10.1093/jac/dky492

61. Tryfinopoulou K, Linkevicius M, Pappa O, Alm E, Karadimas K, Svartström O, et al. Emergence and persistent spread of carbapenemase-producing Klebsiella pneumoniae high-risk clones in Greek hospitals, 2013 to 2022. Eurosurveillance. 2023;28: 2300571. doi:10.2807/1560-7917.ES.2023.28.47.2300571

62. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci U S A. 2015;112: E3574–E3581. doi:10.1073/pnas.1501049112

63. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, et al. Diversity, virulence, and antimicrobial resistance of the KPC-producing Klebsiella pneumoniae ST307 clone. Microb Genomics. 2017;3: e000110. doi:10.1099/mgen.0.000110

64. Hetland MAK, Hawkey J, Bernhoff E, Bakksjø R-J, Kaspersen H, Rettedal SI, et al. Within–patient and global evolutionary dynamics of Klebsiella pneumoniae ST17. Microb Genomics. 2023;9: 001005. doi:10.1099/mgen.0.001005

65. Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, et al. Klebsiella pneumoniae ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid in a resource-constrained healthcare setting. J Antimicrob Chemother. 2020;75: 896–902. doi:10.1093/jac/dkz550

66. Okomo U, Gon G, Darboe S, Sey ICM, Nkereuwem O, Leigh L, et al. Assessing the impact of a cleaning programme on environmental hygiene in labour and neonatal wards: an exploratory study in The Gambia. Antimicrob Resist Infect Control. 2024;13: 36. doi:10.1186/s13756-024-01393-6

67. Bebell L, Muiru A. Antibiotic use and emerging resistance—how can resource-limited countries turn the tide? Glob Heart. 2014;9: 347–358. doi:10.1016/j.gheart.2014.08.009

68. Penzias RE, Bohne C, Gicheha E, Molyneux EM, Gathara D, Ngwala SK, et al. Quantifying health facility service readiness for small and sick newborn care: comparing standards-based and WHO level-2 + scoring for 64 hospitals implementing with NEST360 in Kenya, Malawi, Nigeria, and Tanzania. BMC Pediatr. 2024;23: 656. doi:10.1186/s12887-024-04578-5

69. Nyantakyi E, Baenziger J, Caci L, Blum K, Wolfensberger A, Dramowski A, et al. Investigating the implementation of infection prevention and control practices in neonatal care across country income levels: a systematic review. Antimicrob Resist Infect Control. 2025;14: 8. doi:10.1186/s13756-025-01516-7

70. CDC. Infection Control Assessment and Response (ICAR) Tool for General Infection Prevention and Control (IPC) Across Settings. In: Healthcare-Associated Infections (HAIs) [Internet]. 2 Dec 2024 [cited 24 Sept 2025]. Available: https://www.cdc.gov/healthcare-associated-infections/php/toolkit/icar.html

71. World Health Organization. Infection prevention and control assessment framework at the facility level. 2018 [cited 24 Sept 2025]. Available: https://iris.who.int/items/e7b27920-31ab-4e84-afd0-dc36055ca266

72. Hyland P, Jacobs J, Hardy L. The cost of blood cultures: a barrier to diagnosis in low-income and middle-income countries. Lancet Microbe. 2025;6: 101125. doi:10.1016/j.lanmic.2025.101125

1035   73. Iregbu K, Zhang R, Zhou Y, Walsh TR. Global health equity and diagnosis of sepsis in
1036   low-income and middle-income countries. Lancet Microbe. 2025;6: 101158.
1037   doi:10.1016/j.lanmic.2025.101158

1038   74. Vurayai M, Strysko J, Kgomanyane K, Bayani O, Mokomane M, Machiya T, et al.
1039   Characterizing the bioburden of ESBL-producing organisms in a neonatal unit using
1040   chromogenic culture media: a feasible and efficient environmental sampling method.
1041   Antimicrob Resist Infect Control. 2022;11: 14. doi:10.1186/s13756-021-01042-2

1042   75. World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic
1043   book. 2022 [cited 4 Nov 2025]. Available:
1044   https://www.who.int/publications/i/item/9789240062382

1045   76. Verani JR, Blau DM, Gurley ES, Akelo V, Assefa N, Baillie V, et al. Child deaths caused
1046   by Klebsiella pneumoniae in sub-Saharan Africa and south Asia: a secondary analysis
1047   of Child Health and Mortality Prevention Surveillance (CHAMPS) data. Lancet Microbe.
1048   2024;5: e131–e141. doi:10.1016/S2666-5247(23)00290-2

1049   77. Okomo UA, Darboe S, Bah SY, Ayorinde A, Jarju S, Sesay AK, et al. Maternal
1050   colonization and early-onset neonatal bacterial sepsis in the Gambia, West Africa: a
1051   genomic analysis of vertical transmission. Clin Microbiol Infect. 2023;29: 386.e1-
1052   386.e9. doi:10.1016/j.cmi.2022.10.012

1053

1054
1055

Supporting Information Captions

1057 **S1 Table. Ethics committees approving individual studies.** Approval for the analysis presented
1058 here was granted by the Observational / Interventions Research Ethics Committee of the London
1059 School of Hygiene and Tropical Medicine (ref #29931), and covers inclusion of data from the studies
1060 whose primary ethical approvals are listed in this table.
1061

1062 **S2 Table. Studies included in the analysis.** Details of type of study, number of isolates; laboratory
1063 methods for identification, storage, DNA extraction, sequencing; informatics methods for quality
1064 control and assembly; BioProject accession and citation/s for primary study.
1065

1066 **S3 Table. Isolates and sequence data included in the study.**
1067

1068 **S4 Table. Clusters identified in the study.**
1069

1070 **S5 Table. Summary of *Klebsiella pneumoniae* STs identified in the study.**
1071

1072 **S6 Table. Chi squared tests of resistance distribution by cluster status.** Only one isolate was
1073 included per cluster, and the representative cluster isolate was assigned the consensus ESBL or
1074 carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was
1075 recorded as ESBL-positive).
1076

1077 **S7 Table. Logistic regression model for transmission.** Multivariable logistic regression model to
1078 assess factors associated with transmission clusters. Each unique 'introduction' (i.e. cluster, or

unclustered singleton case) was treated as an observation, with the outcome recorded as transmission (cluster size ≥2) or no transmission (unclustered singleton case). For each cluster, each predictor was assigned the consensus value for that cluster (e.g. if 3 of 4 cases were ESBL, the cluster was recorded as ESBL). Predictors ST, Site, K locus, and O type were encoded categorical variables. AMR variables (ESBL gene and carbapenemase gene presence) were encoded as binary. Commonly transmitted STs were defined as those that were identified in ≥3 transmission clusters in two or more sites; other STs were categorised as 'Other' and used as the reference category. The top 10 K loci were encoded as individual categories and compared to all other K loci as the reference category. O types were compared to the most common O type (51.6%) as the reference category. ESBL+: ESBL or carbapenemase gene carriage (Kleborate resistance score ≥ 1); CP+: carbapenemase gene carriage (Kleborate resistance score ≥ 2).

S8 Table. Chi squared tests of resistance distribution by ST type. Only one isolate was included per cluster, and the representative cluster isolate was assigned the consensus ESBL or carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was recorded as ESBL-positive).

S9 Table. Summary of O serogroups detected. Only one isolate was counted per cluster, and the representative cluster isolate was assigned the consensus ESBL or carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was recorded as ESBL-positive).

S10 Table. Summary of K loci detected. Only one isolate was counted per cluster, and the representative cluster isolate was assigned the consensus ESBL or carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was recorded as ESBL-positive).

S1 Figure. Flow diagram for inclusion of isolates. All numbers shown represent the number of isolates. For the line 'Sites with N<10 pass filters', the numbers represent the total number of isolates excluded for all excluded sites.

S2 Figure. Geotemporal distribution of isolates included in the analysis. (A) Location of study sites. Each point represents a unique site and point sizes indicate the number of isolates included per site, as per figure legend. Country colours indicate the number of isolates included per country, as per figure legend. The map was generated using the rnaturalearth (version 1.0.1) package in R. Base map source: Natural Earth, https://www.naturalearthdata.com/downloads/10m-cultural-vectors/, accessed using rnaturalearth R package v1.0.1, terms of use: https://www.naturalearthdata.com/about/terms-of-use/. (B) Plot shows sampling dates for all isolates included per sites. Each point represents a unique isolate included per site and numbers inside the box represent the number of isolates per site. Points are jittered along the y-axis to aid visibility.

S3 Figure. Transmission clusters of *K. pneumoniae* neonatal sepsis cases per study. Each point represents one or more cases isolated on specific dates. Points are coloured according to sequence type. Clusters are represented as groups of cases (points) linked by horizontal lines. Clusters belonging to the same sequence type are jittered along the y-axis to allow visibility of overlapping clusters. ST – sequence type. * – includes single locus variants of the respective STs.

S4 Figure. Sensitivity of the cluster proportion estimates to varying temporal and genetic distance thresholds. The sub-panels show estimates for individual study datasets at different combinations of genetic distance threshold (x-axis) and temporal distance threshold ranges (as per figure legend).

S5 Figure. Cluster proportion vs facility characteristics. (A) Individual site characteristics and estimates of proportion of cases in clusters. (B) Distribution of cluster proportion estimates by facility

1131 characteristics. Panels compare the distribution of proportion of isolates in clusters across different
1132 facility characteristics: (i) Onsite availability of neonatal surgical facilities (ii) Facility size (iii)
1133 Availability of piped water (iv) Number of neonatal beds. Individual points represent cluster
1134 proportions for specific facilities. Facility size – Small: 50–150 beds, Medium: 151–300 beds, Large:
1135 301–600 beds, Very Large: >600 beds. CI: confidence interval
1136
1137 **S1 Appendix. Sensitivity of cluster analysis.**
1138
1139 **S1 Checklist. STrengthening the Reporting of OBservational studies in Epidemiology**
1140 **(STROBE) Statement – checklist of items that should be included in reports of observational**
1141 **studies, available at https://www.strobe-statement.org/, licenced under CC BY 4.0.**
1142
1143
1144

Financial Disclosure Statement

This study was supported by the Gates Foundation [https://www.gatesfoundation.org/]
(grants INV049364, INV025280, INV077266 to KEH; INV049641 to KLW; INV003519 to
AMA; INV005180 to NAF; INV041685 to JAB; INV008112 to NPG; INV005567 to CCT;
INV005691 to DHH; INV005773 to SAM; INV065400 to AMM; INV065400 to SEC), the
Fleming Fund [https://www.flemingfund.org/] (grant FF25-286 for SeqAfrica to support
sequencing capacity at KCRI), the Thrasher Research Fund
[https://www.thrasherresearch.org/] (grant #12036 to DHH), the Center for AIDS Research
[https://www.niaid.nih.gov/research/centers-aids-research] (core support grant to SEC), the
Wellcome Trust [https://wellcome.org] (grant 217303/Z/19/Z to EH, core support grants
206194 to WSI, 206454 to MLW, 203077/Z/16/Z to KWTRP), and the National Health and
Medical Research Council of Australia [https://www.nhmrc.gov.au/] (APP1176192 to KLW).
Pfizer [https://www.pfizer.com/] sponsored the sequencing of a subset of isolates from the
GBS-COP study for WITS-Vida (SAM). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript. The
conclusions and opinions expressed in this work are those of the author(s) alone and shall
not be attributed to any funder. Under the grant conditions of the Gates Foundation and
Wellcome Trust, a Creative Commons Attribution 4.0 License has already been assigned to
the Author Accepted Manuscript version that might arise from this submission. Please note
works submitted as a preprint have not undergone a peer review process.

Author contribution statement

Conceptualization: Kathryn E Holt

Data Curation: Jabir A Abdulahi, Anne V Amulele, Matthew Bates, Eva Heinz, Weiming Hu, Kajal Jain, Rindidzani Magobo, Courtney P Olwagen, John M Tembo, Tolbert Sonda, Jonathan Strysko, Caroline C Tigoi

Formal Analysis: Erkison Ewomazino Odih, Kathryn E Holt

Funding Acquisition: Ramesh K Agarwal, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Kathryn E Holt, Shabir A Madhi, M Jeeva Sankar, Kelly L Wyres

Investigation: Kyle Bittinger, Jennifer Cornick, Ebenezer Foster-Nyarko, Wilson Gumbi, Steven M Jones, Chileshe Lukwesa, Carolyn M McGann, Ahmed M Moustafa, Patrick Musicha, James CL Mwansa, Moreka L Ndumba, Donwilliams O Omuoyo, Oliver Pearse, Laura T Phillips, Paul J Planet, Charlene MC Rodrigues, Fatou Secka, Kirsty Sands, Jonathan Strysko, Erin Theiller, Allan M Zuza

Methodology: Erkison Ewomazino Odih, Kathryn E Holt, Kelly L Wyres

Resources: Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Kajal Jain, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Anudita Bhargava, Atul Jindal, Ramesh K Agarwal, M Jeeva Sankar, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi,

Software: Erkison Ewomazino Odih, Thomas D Stanton

Supervision: Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Kajal Jain, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Anudita Bhargava, Atul Jindal, Ramesh K Agarwal, M Jeeva Sankar, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi,

Visualization: Erkison Ewomazino Odih, Kathryn E Holt

Writing – Original Draft Preparation: Erkison Ewomazino Odih, Kathryn E Holt

Writing – Review & Editing: All authors.